Physician profile
Anna Burgansky
NPI 1639195209
$1,642.48
in general payments reported to CMS, 2019-2025
22 companies · $498 in 2025
The $498 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $120 · 2021: $153 · 2022: $93.18 · 2023: $136 · 2024: $277 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $244.02 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $161.34 | 2025 | |
| Abbvie INC. | $152.03 | 2019-2023 | Lo Loestrin Fe |
| Alydia Health | $139.37 | 2021 | |
| Therapeuticsmd, INC. | $128.56 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $126.31 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $109.11 | 2023-2025 | Gemtesa, Myfembree |
| Exeltis, USA INC. | $88.01 | 2025 | Slynd |
| Organon LLC | $79.28 | 2023-2024 | Nexplanon |
| Coopersurgical, INC. | $73.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.44 | 2019-2020 | |
| Avion Pharmaceuticals | $42.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $36.00 | 2019 | |
| Millicent US INC | $30.95 | 2019-2025 | Femlyv, Intrarosa |
| Botanix Sb INC | $30.32 | 2025 | Sofdra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.77 | 2025 | Aptima |
| Evofem Biosciences, INC. | $21.07 | 2024 | |
| Amag Pharmaceuticals, INC. | $18.36 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.18 | 2019 | |
| Allergan, INC. | $16.18 | 2019 | |
| Currax Pharmaceuticals LLC | $15.73 | 2025 | Contrave |
| Meditrina | $15.06 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Burgansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.